MAPK8 and colorectal carcinoma: In examining conventional chemotherapy susceptibility based on the prognostic signature, Gefitinib, PLX4720, AZD.2281, cisplatin, and JNK.inhibitor.VIII were all more efficient for CRC patients in the high-risk group compared to CRC patients in the low-risk group.